Bradycor bradykinin antagonist: Began a Phase II trial in 160 patients. End points will be improved intracranial pressure and outcome on the Glasgow Coma Score,

Cortech Inc. (CRTQ), Denver Product: Bradycor bradykinin antagonist Indication: Traumatic brain injury Status: Began a Phase II trial in 160 patients. End points will be improved intracranial pressure...